Bucking the trend, Antares gains FDA OK for testosterone injection on second try
A year after its testosterone replacement therapy was spurned at the FDA, Antares Pharma has snatched an OK from an agency that has made its dislike for such treatments well known.
Antares can now begin marketing three different doses of Xyosted, a subcutaneous auto-injector containing testosterone enanthate, though the approval does come with a boxed warning about blood pressure increases and subsequent elevated risk for cardiovascular problems.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
